Rahul Aggarwal
Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.
Overview
Rahul Aggarwal is Associate Director for Clinical Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist specialising in prostate cancer, neuroendocrine prostate cancer and PSMA theranostics, he leads UCSF's early-phase and prostate cancer clinical research and defined treatment-emergent small-cell neuroendocrine prostate cancer, the way tumours transform to escape hormone therapy. His papers include a multi-institutional prospective study characterising that disease clinically and genomically, and a report on heterogeneous flare in PSMA PET tracer uptake after starting androgen pathway blockade. He leads PSMA radioligand and combination trials, including with lutetium-177 vipivotide tetraxetan.
Similar pages
not linked directly; found by shared links- PersonThomas A. Hope
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonLouise Emmett
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- CompanyARTBIO
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer, Lutetium-177.
- PersonEmily K. Bergsland
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters), Lutetium-177.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- CollectionProstate Cancer Foundation (PCF)
Shares PSMA, Lutetium-177 vipivotide tetraxetan, PSMA PET, Prostate cancer.